Catalyst Pharmaceuticals, Inc.
US ˙ NASDAQCM ˙ US14888U1016 ˙ Medical Devices
DIESES SYMBOL IST NICHT MEHR AKTIV

SecurityCPRX / Catalyst Pharmaceuticals, Inc.
InstitutionFESM - Fidelity Enhanced Small Cap ETF
Latest Disclosed Ownership225,520 shares
Latest Disclosed Value $ 5,583,875
FESM - Fidelity Enhanced Small Cap ETF reports 21.21% increase in ownership of CPRX / Catalyst Pharmaceuticals, Inc.

On May 26, 2026 - FESM - Fidelity Enhanced Small Cap ETF filed a NPORT-P form disclosing ownership of 225,520 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX) valued at $5,583,875 USD as of March 31, 2026. The entity filed a previous NPORT-P on February 24, 2026 disclosing 186,052 shares of Catalyst Pharmaceuticals, Inc.. This represents a change in shares of 21.21% during the quarter. The current value of the position is $7,101,625 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-26 2026-03-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 225,520 39,468 21.21 5,584 28.58 0.1362
2026-02-24 2025-12-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 186,052 42,405 29.52 4,342 53.48 0.1294
2025-11-25 2025-09-30 NP CATALYST PHARMACEUTICALS EC US14888U1016 143,647 18,855 15.11 2,830 4.51 0.1133
2025-08-22 2025-06-30 NP CATALYST PHARMACEUTICALS EC US14888U1016 124,792 5,880 4.94 2,708 -6.10 0.1426
2025-05-27 2025-03-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 118,912 49,991 72.53 2,884 100.49 0.1730
2025-02-25 2024-12-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 68,921 8,745 14.53 1,438 20.23 0.1350
2024-11-25 2024-09-30 NP CATALYST PHARMACEUTICALS EC US14888U1016 60,176 18,697 45.08 1,196 86.29 0.1294
2024-08-27 2024-06-30 NP CATALYST PHARMACEUTICALS EC US14888U1016 41,479 4,830 13.18 643 9.93 0.1075
2024-05-23 2024-03-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 36,649 11,510 45.79 584 45.27 0.1117
2024-04-24 2024-02-29 NP CATALYST PHARMACEUTICALS EC US14888U1016 25,139 21,060 516.30 403 593.10 0.0783
2024-01-24 2023-11-30 NP CATALYST PHARMACEUTICALS EC US14888U1016 4,079 4,079 59 0.0130
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.